US · Healthcare · Biotechnology
EPS came in at -1.11 against a street estimate of -1.16 — a beat of 4.3%.
Analysts rate Xenon Pharmaceuticals Inc a strong buy (19 buy, 0 hold, 0 sell out of 19) with an average price target of $81.21.
CONFIDENT Xenon advanced AZK NDA submission for focal seizures with best-in-class efficacy data. Expanding into depression/bipolar via Phase 3 trials, expecting MDD data H1 2027. Pain pipeline progressing with two Nav1.7/Kv7 Phase 1 programs nearing completion; added second Nav1.7 candidate. Q2 2026 U.S. focus for AZK NDA submission. X-TOLE3 includes Japanese enrollment for non-U.S. regulatory pathways. Analysts pressed on pre-NDA meeting details (resolved: productive, no agency concerns), pain safety/cardiac risk (resolved: profile comfortable for Phase 2), and general neuro adoption timing (resolved: expected sooner than typical ASM launches via service-wrapped distribution). Management confident but deferred specifics on Phase 2 pain trial design and depression efficacy thresholds. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 11.17% |
| venBio Select Advisor LLC | 5.97% |
| BlackRock Inc | 5.82% |
| Driehaus Capital Management LLC | 4.64% |
| Polar Capital Holdings PLC | 4.55% |
| HHG PLC | 4.31% |
| Capital Research & Mgmt Co - Division 3 | 2.44% |
| JPMorgan Chase & Co | 1.99% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 XENON PHARMACEUTICALS INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $119.5 million in cash and equivalents as of June 30, 2026 (do | 2026-08-06 |
| Results announced · Q3 2026 XENON PHARMACEUTICALS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and marketable securities: $1,245.1 million as of | 2026-08-06 |
| Board / officer change · Q2 2026 XENON PHARMACEUTICALS INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 2, 2026 • 90,399,636.29 common shares voted, repres | 2026-06-03 |
| Quarterly report · Q1 2026 XENON PHARMACEUTICALS INC. — FORM 10-Q SUMMARY For Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash & Securities Position: $1,339,621 thous | 2026-05-07 |
| Results announced · Q2 2026 XENON PHARMACEUTICALS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $1,339.6 million as of | 2026-05-07 |
| Proxy statement · Q2 2026 XENON PHARMACEUTICALS INC. – PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Item 1: Receipt of financial statements for the year ended De | 2026-04-22 |
| Board / officer change · Q2 2026 XENON PHARMACEUTICALS INC. - 8-K SUMMARY HEADLINE NUMBERS • Stock incentive plan share pool increased by 275,000 shares (from 900,000 to 1,175,000 s | 2026-04-13 |
| Annual report FY2025 XENON PHARMACEUTICALS INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market Capitalization (June 30, 2025): $2,404.9 million (publicly | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Positive Phase 3 data reported; NDA submission planned Q3 2026 Xenon Pharmaceuticals announced positive Phase 3 results for azetukalner, its lead drug candidate for focal onset seizures (FOS). The X-TOLE2 study exceeded expectations, showing the highest | 2026-05-07 |
| Q4 2025 results; Phase 3 data milestones expected H1 2026-H1 2027 Xenon Pharmaceuticals, a biotech company developing neurological treatments, reported Q4 2025 results with strong clinical progress on its lead drug azetukalner. Key highlights: Phase 3 X-TO | 2026-02-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Xenon Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.